LOGIN  |  REGISTER
Chimerix
Astria Therapeutics

Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025

November 04, 2025 | Last Trade: US$0.76 0.05 -6.21

BELGRADE, Mont., Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the start of trading on Tuesday, November 11, 2025.

Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day.

Conference Details:

Conference Date: Tuesday, November 11, 2025
Conference Time: 8:30 AM ET
Conference Dial-in: 888-506-0062
International Dial-in: 973-528-0011
Passcode: 579614
Conference Call Name: Xtant Medical Q3 2025 Financial Results
Webcast link: https://www.webcaster5.com/Webcast/Page/3039/52972

Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor info."

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page